Company intelligence / Profile preview

DAAN Cancer Research Institute

Seoul, Seoul-teukbyeolsi, South Korea

Ownership: Private
Development stage: Other

Overview

DAAN Biotherapeutics is progressing preclinical pipelines of cell therapies and antibody therapeutics targeting lung cancer (notably EGFR mutations) and various solid tumors, leveraging innovative platforms for antigen discovery and single-cell analysis. It has established major partnerships to advance programs toward clinical development but lacks reported clinical human data as of 2025

Therapeutic areas: Oncology
Modalities: Cell therapyAntibodyBispecific antibodySmall molecule inhibitor
Industry: Academic Hospital/University/Research

Partnerships

GC CellLigaChem BiosciencesGenScript ProBioYonsei New Il Han Institute for Integrative Cancer ResearchLatvian government

Beyond the preview

Go deeper on DAAN Cancer Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAAN Cancer Research Institute.

Explore the full profile